Evidence map›Paper›PMID 32492022›Full record

ArticlePloS one2020

Designing an optimized diagnostic network to improve access to TB diagnosis and treatment in Lesotho.

Heidi Albert, Ryan Purcell, Ying Ying Wang, Kekeletso Kao, Mathabo Mareka, Zachary Katz, Bridget Llang Maama, Tsietso Mots'oane

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Heidi AlbertFIND, Cape Town, South Africa.ORCID 0000-0002-8595-4123
Ryan PurcellLLamasoft Inc., St. Ann Arbor, MI, United States of America.
Ying Ying WangLLamasoft Inc., St. Ann Arbor, MI, United States of America.
Kekeletso KaoFIND, Geneva, Switzerland.
Mathabo MarekaNational Tuberculosis Reference Laboratory, Ministry of Health, Maseru, Lesotho.
Zachary KatzFIND, Geneva, Switzerland.
Bridget Llang MaamaNational Tuberculosis Programme, Ministry of Health, Maseru, Lesotho.
Tsietso Mots'oaneDirectorate of Laboratory Services, Ministry of Health, Maseru, Lesotho.
Ministry of Health · LSFIND · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo reach WHO End tuberculosis (TB) targets, countries need a quality-assured laboratory network equipped with rapid diagnostics for tuberculosis diagnosis and drug susceptibility testing. Diagnostic network analysis aims to inform instrument placement, sample referral, staffing, geographical prioritization, integration of testing enabling targeted investments and programming to meet priority needs.

methodsSupply chain modelling and optimization software was used to map Lesotho's TB diagnostic network using available data sources, including laboratory and programme reports and health and demographic surveys. Various scenarios were analysed, including current network configuration and inclusion of additional GeneXpert and/or point of care instruments. Different levels of estimated demand for testing services were modelled (current [30,000 tests/year], intermediate [41,000 tests/year] and total demand needed to find all TB cases [88,000 tests/year]).

resultsLesotho's GeneXpert capacity is largely well-located but under-utilized (19/24 sites use under 50% capacity). The network has sufficient capacity to meet current and near-future demand and 70% of estimated total demand. Relocation of 13 existing instruments would deliver equivalent access to services, maintain turnaround time and reduce costs compared with planned procurement of 7 more instruments. Gaps exist in linking people with positive symptom screens to testing; closing this gap would require extra 11,000 tests per year and result in 1000 additional TB patients being treated. Closing the gap in linking diagnosed patients to treatment would result in a further 629 patients being treated. Scale up of capacity to meet total demand will be best achieved using a point-of-care platform in addition to the existing GeneXpert footprint.

conclusionsAnalysis of TB diagnostic networks highlighted key gaps and opportunities to optimize services. Network mapping and optimization should be considered an integral part of strategic planning. By building efficient and patient-centred diagnostic networks, countries will be better equipped to meet End TB targets.

Indexed as

Community NetworksAntibiotics, AntitubercularClinical Laboratory ServicesDNA, BacterialDrug Resistance, BacterialHumansLesothoMicrobial Sensitivity TestsModels, TheoreticalMycobacterium tuberculosisNucleic Acid Amplification TechniquesPoint-of-Care SystemsRifampinSoftwareTuberculosis, PulmonaryAntibiotics, AntitubercularDNA, BacterialRifampin

Identifiers

PMID32492022
PMCPMC7269260
OpenAlexW3030748629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.